RLYB Stock Summary and Trading Ideas (Rallybio | NASDAQ:RLYB)

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Rallybio trades on the NASDAQ stock market under the symbol RLYB.

As of August 20, 2026, RLYB stock price declined to $16.66 with 5,196 million shares trading.

RLYB has a beta of 0.52, meaning it tends to be less sensitive to market movements. RLYB has a correlation of 0.01 to the broad based SPY ETF.

RLYB has a market cap of $88.41 million. This is considered a Micro Cap stock.

In the last 3 years, RLYB traded as high as $47.68 and as low as $1.76.

The top ETF exchange traded funds that RLYB belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.

RLYB has outperformed the market in the last year with a price return of +266.0% while the SPY ETF gained +20.7%. RLYB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.4% and +3.2%, respectively, while the SPY returned +4.5% and -0.7%, respectively.

RLYB support price is $16.60 and resistance is $17.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLYB shares will trade within this expected range on the day.